TREVICTA is a long-acting injectable form of paliperidone palmitate, which is used in the treatment of schizophrenia. It is designed to be administered once every three months, providing a sustained release of medication to help manage the symptoms of this mental health condition over an extended period. TREVICTA works by affecting the balance of chemicals in the brain, particularly dopamine and serotonin, which can be involved in schizophrenia. This medication is intended for use in adults who have already been treated with paliperidone palmitate one-month injectable product or who have been stabilized on risperidone. By offering a long-acting treatment option, TREVICTA aims to improve adherence to medication, reduce the frequency of hospital visits for injections, and provide a more consistent control of symptoms, thereby improving the quality of life for individuals living with schizophrenia.